drugset / Trial / NCT01149668

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

NCT01149668

Phase 1 Completed 7 enrolled Pharmacyclics LLC.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the long-term (\> 6 months) safety of PCI 24781 PO in subjects with lymphoma.

Timeline

Start
2010-06
Primary completion
2012-12
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Abexinostat Small molecule Oral